by Admin Neo Lumina | Sep 28, 2023 | Press Release
NeoLumina Bioscience In-Licenses Clinical-stage Psilocybin Product Candidate from Filament Health for Eating Disorders PEX010 expands NeoLumina’s psychedelic product pipeline. Funding activity in process to advance clinical development. VANCOUVER, BRITISH COLUMBIA,...
by Admin Neo Lumina | Sep 25, 2023 | News
Psilocybin might be effective for treatment-resistant depression even with ongoing SSRI use, study suggests In a new exploratory phase II clinical trial, a single dose of psilocybin, when used as an adjunct to ongoing SSRI treatment and combined with supportive...
by Admin Neo Lumina | Sep 14, 2023 | News
Psychedelic Drugs Market revenue to exceed USD 12 Billion by 2035, says Research Nester Leading psychedelic drugs market players include Research Nester are COMPASS Pathways plc, Silo Pharma, Inc., Numinus Wellness Inc., Cybin Inc., Mind Medicine Inc., Jazz...
by Admin Neo Lumina | Sep 7, 2023 | News
Filament Health Announces FDA Approval Of Two Clinical Trials Studying Its Botanical Psilocybin Drug Candidate PEX010 The University of Washington and the University of California, Los Angeles have been approved to study PEX010 in clinical trials for mental health...
by Admin Neo Lumina | Sep 7, 2023 | News
New Study Shows Candy-Flipping Can Reduce Bad Trips A new study published in Nature shows that MDMA can reduce difficult experiences with other psychedelics. “Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive...
